Mycoplasma pneumoniae in adult community-acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells

Medical Science Monitor

Volumn 18, Issue 8, 2012, Pages

  Puljiz, Ivan ^a   Markotić, Alemka ^a   Krajinović, Lidija Cvetko ^a   Gužvinec, Marija ^a   Polašek, Ozren ^b   Kuzman, Ilija ^a  

^a Croatia   (Croatia)

^b UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Community acquired pneumonia; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Mycoplasma pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; GELATINASE A; GELATINASE B;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MALE; MYCOPLASMA PNEUMONIAE; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL CIRCULATION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84866124049     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883270     Document Type: Article

References (27)

1. Marston BJ, Plouffe JF, File TM Jr et al: Incidence of community-acquired pneumonia requiring hospitalization. Results of a populationbased active surveillance study in Ohio. Arch Intern Med, 1997; 157: 1709-18
2. Porath A, Schlaeffer F, Lieberman D: The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect, 1997; 34: 41-48
3. Waites KB, Talkington DF: Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev, 2004; 17: 697-728
4. Wisse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res, 2003; 92: 827-39
5. Elkington PT, Friedland JS: Matrix metalloproteinases in destructive pulmonary pathology. Thorax, 2006; 61: 259-66
6. Ohbayashi H: Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci, 2002; 3: 409-21
7. Suga M, Iyonaga K, Okamoto T et al: Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 2000; 162: 1949-56
8. Buisson AC, Zahm JM, Polette M et al: Gelatinase B is involved in the in vitro wound repair of human respiratory epithelium. J Cell Physiol, 1996; 16: 413-26
9. D'Ortho MP, Jarreau PH, Delacourt C et al: Matrix metalloproteinase and elastase activies in LPS-induced acute lung injury in guinea pigs. Am J Physiol, 1994; 266: 209-16
10. Takafuji S, Ishida A, Miyakuni Y, Nakagawa T: Matrix metalloproteinase-9 release from human leukocytes. J Investig Allergol Clin Immunol, 2003; 13: 50-55
11. Yao PM, Buhler JM, d'Ortho MP et al: Expression of matrix metalloproteinase gelatinases A and B by cultured epithelial cells from human bronchial explants. J Biol Chem, 1996; 271: 15580-89
12. Segura-Valdez L, Pardo A, Gaxiola M et al: Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest, 2000; 117: 684-94
13. Puljiz I, Kuzman I, Dakovic-Rode O, Schönwald N, Mise B: Chlamydia pneumonia and Mycoplasma pneumoniae pneumonia: Comparison of clinical, epidemiological characteristics and laboratory profilesm. Epidemiol Infect, 2006; 134: 548-55
14. Haidopoulou K, Goutaki M, Damianidou L et al: Human bocavirus infections in hospitalized Greek children. Arch Med Sci, 2010; 1: 100-3
15. Schaaf B, Liebau C, Kurowski V et al: Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteniase activity. BMC Pulm Med, 2008; 8: 12
16. Hartog CM, Wermelt JA, Sommerfeld CO et al: Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia Am J Resp Crit Care Med, 2003; 167: 593-98
17. Yang SF, Chu SC, Chiang IC et al: Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta, 2005; 352; 209-15
18. Cowland JB, Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics, 1997; 45: 17-23
19. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol, 1997; 74: 111-22
20. Sakellaropoulou A, Hatzistilianou M, Eboriadou M, Athanasiadou-Piperopoulou F: Hyponatraemia in cases of children with pneumonia. Arch Med Sci, 2010; 4: 578-83
21. Lichtinghagen R, Huegel O, Seifert T et al: Expression of matrix metalloproteinase-2 and-9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chemistry, 2000; 46: 183-92
22. Baluk P, Raymond WW, Ator E et al: Matrix metalloproteinase-2 and-9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol, 2004; 287: 307-17
23. Kim JY, Choeng HC, Ahn C, Cho SH: Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med J, 2009; 50: 68-77
24. Torii K, Iida K, Miyazaki Y et al: Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med, 1997; 155: 43-46
25. Piotrowski WJ, Gorski P, Pietras T et al: The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit, 2011; 17(10): CR598-607
26. Bottcher T, Spreer A, Azeh I et al: Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci Lett, 2003; 338: 201-4
27. Opdenakker G, Van den Steen PE, Dubois B et al: Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol, 2001; 69: 851-59